Definium Therapeutics annual return on equity
2021
2022
2023
2024
2025
Definium Therapeutics Return on Equity (ROE) Growth & History (DFTX)
Definium Therapeutics's return on equity was −64.06% for fiscal 2025.
View full Definium Therapeutics company overviewDefinium Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −64.06% | +3.95 pp |
| 2024 | 2024-12-31 | −68.01% | +15.58 pp |
| 2023 | 2023-12-31 | −83.59% | −46.05 pp |
| 2022 | 2022-12-31 | −37.54% | +44.24 pp |
| 2021 | 2021-12-31 | −81.78% | — |
Definium Therapeutics quarterly return on equity
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −26.55% | −5.61 pp |
| Q1 2026 | 2026-03-31 | −25.23% | −15.17 pp |
| Q4 2025 | 2025-12-31 | −21.79% | −7.99 pp |
| Q3 2025 | 2025-09-30 | −42.57% | −36.68 pp |
| Q2 2025 | 2025-06-30 | −20.94% | −18.00 pp |
| Q1 2025 | 2025-03-31 | −10.06% | +29.62 pp |
| Q4 2024 | 2024-12-31 | −13.80% | +13.62 pp |
| Q3 2024 | 2024-09-30 | −5.90% | +11.85 pp |
| Q2 2024 | 2024-06-30 | −2.94% | +21.71 pp |
| Q1 2024 | 2024-03-31 | −39.68% | −22.03 pp |
| Q4 2023 | 2023-12-31 | −27.41% | −24.19 pp |
| Q3 2023 | 2023-09-30 | −17.75% | −5.89 pp |
| Q2 2023 | 2023-06-30 | −24.65% | −11.67 pp |
| Q1 2023 | 2023-03-31 | −17.65% | −4.85 pp |
| Q4 2022 | 2022-12-31 | −3.22% | +11.57 pp |
| Q3 2022 | 2022-09-30 | −11.86% | — |
| Q2 2022 | 2022-06-30 | −12.98% | — |
| Q1 2022 | 2022-03-31 | −12.79% | — |
| Q4 2021 | 2021-12-31 | −14.79% | — |
Definium Therapeutics return on equity trends
Between the periods ended 2021-12-31 and 2025-12-31, Definium Therapeutics's return on equity increased from −81.78% to −64.06%, a change of +17.71 percentage points. The latest reported quarter, Q2 2026, shows −26.55%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Definium Therapeutics source filings ↗